GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » Accumulated Depreciation

Editas Medicine (Editas Medicine) Accumulated Depreciation : $-27.57 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Editas Medicine's quarterly accumulated depreciation increased from Sep. 2023 ($-25.01 Mil) to Dec. 2023 ($-26.26 Mil) and increased from Dec. 2023 ($-26.26 Mil) to Mar. 2024 ($-27.57 Mil).

Editas Medicine's annual accumulated depreciation increased from Dec. 2021 ($-15.51 Mil) to Dec. 2022 ($-21.53 Mil) and increased from Dec. 2022 ($-21.53 Mil) to Dec. 2023 ($-26.26 Mil).


Editas Medicine Accumulated Depreciation Historical Data

The historical data trend for Editas Medicine's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Accumulated Depreciation Chart

Editas Medicine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.20 -11.10 -15.51 -21.53 -26.26

Editas Medicine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.96 -23.49 -25.01 -26.26 -27.57

Editas Medicine Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


Editas Medicine Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine (Editas Medicine) Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Executives
Bruce Eaton officer: EVP, Chief Business Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Linda Burkly officer: EVP, CHIEF SCIENTIFIC OFFICER 1 MAIN STREET, CAMBRIDGE MA 02142
Baisong Mei officer: SVP, CHIEF MEDICAL OFFICER C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill director, officer: CEO 215 FIRST STREET, CAMBRIDGE MA 02142
Erick Lucera officer: EVP, CHIEF FINANCIAL OFFICER 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Michelle Robertson officer: Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman officer: EVP, Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels officer: EVP/Chief Medical Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton director C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen director 940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cynthia Collins director 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142

Editas Medicine (Editas Medicine) Headlines